Lung Cancer

MD IQ

Conference Coverage

Adding MET TKI may overcome NSCLC resistance

ATLANTA – Combining the investigational MET inhibitor savolitinib to osimertinib was associated with responses in NSCLC resistant to EGFR-targeted...

Pages